Globela Pharma

Surat, India Founded: 1996 • Age: 30 yrs
Finished formulations like tablets, capsules, syrups, and injectables are manufactured.
Annual revenue $30.5M Latest available
Total funding $11.4M 3 rounds
Employees 150 Tracked headcount
Investors 8 Known backers
Products 4 Services tracked
Competitors 9 Brand Intelligence

About Globela Pharma

Globela Pharma is a company based in Surat (India) founded in 1996. Globela Pharma has raised $11.37 million across 3 funding rounds from investors including Somerset Indus Capital Partners, Karthic Jayaraman and Firoze Jehangir Irani. The company has 150 employees as of March 08, 2025. Globela Pharma offers products and services including Finished Dosage Formulations, APIs, Intermediates, and DC Granules and Pellets. Globela Pharma operates in a competitive market with competitors including Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.

  • Headquarter Surat, India
  • Employees 150 as on 08 Mar, 2025
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Globela Pharma Pvt Ltd
  • Jurisdiction Surat, Gujarat, India
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $30.53 M (USD)
    26.6
    as on Mar 31, 2024
  • Net Profit
    -$797.81 K (USD)
    -227.12
    as on Mar 31, 2024
  • EBITDA
    $2.19 M (USD)
    -10.54
    as on Mar 31, 2024
  • Total Equity Funding
    $11.37 M (USD)

    in 3 rounds

  • Latest Funding Round
    $3.39 M (USD), Unspecified

    Jan 11, 2022

  • Investors
  • Employee Count
    150

    as on Mar 08, 2025

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Globela Pharma

Globela Pharma offers a comprehensive portfolio of products and services, including Finished Dosage Formulations, APIs, Intermediates, and DC Granules and Pellets.

Product name locked
Category locked
Primary

High-quality drugs for therapeutic areas like oncology

Product name locked
Category locked
Locked

Raw materials for drug manufacturing and innovation

Product name locked
Category locked
Locked

Semi-finished products for pharmaceutical applications

Product name locked
Category locked
Locked

Components for drug production and delivery systems

People of Globela Pharma

Headcount 200-500
Employee Profiles 2
Employee Profiles
People
Bhanu Vaghashia
Managing Director
People
Disha Patel
Quality Assurance Executive

Unlock access to complete

Teams

Funding Insights of Globela Pharma

Globela Pharma has successfully raised a total of $11.37M across 3 strategic funding rounds. The most recent funding activity was a Unspecified round of $3.39 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Globela Pharma

Globela Pharma has secured backing from 8 investors, including venture fund and angel investors. Prominent investors backing the company include Somerset Indus Capital Partners, Karthic Jayaraman and Firoze Jehangir Irani.

All
Venture Fund
Angel
Investor Description Founded Year Domain Location
Healthcare investments focused on accessibility, affordability, and ESG integration in India.
Locked Locked Locked

Karthic Jayaraman

Angel investor and tech entrepreneur, co-founder of WayCool Foods, focused on agritech.
Locked Locked Locked

Firoze Jehangir Irani

-
Locked Locked Locked
Premium access

Investor details for Globela Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Globela Pharma

Investments
Premium access

Investment portfolio details for Globela Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Globela Pharma

Premium access

Detailed financials for Globela Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Globela Pharma Comparisons

Globela Pharma Primary company
Description
Finished formulations like tablets, capsules, syrups, and in...
Location
Surat, India
Founded Year
1996
Annual Revenue
$30.53 M (USD)
Net Profit
-$797.81 K (USD)
EBITDA
$2.19 M (USD)
Employees
150
As of 2025
Premium access

Peer comparison for Globela Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Globela Pharma

Globela Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Contract development and manufacturing organization for proprietary and generic drugs
Locked Locked Locked
CDMO focusing on spectrum of dosage forms and therapeutic segments
Locked Locked Locked
Company offering a suite of R&D and manufacturing services for small molecules and generics
Locked Locked Locked
Pharmaceutical development and manufacturing services are offered contractually.
Locked Locked Locked
CDMO with a focus on early phase drug product development
Locked Locked Locked
Cephalosporin APIs and generic formulations are manufactured.
Premium access

Detailed competitors of Globela Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Globela Pharma

Premium access

Complete news archive for Globela Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Globela Pharma

Globela Pharma was founded in 1996 and raised its 1st funding round 15 years after it was founded.

Globela Pharma is headquartered in Surat, India. It is registered at Surat, Gujarat, India.

Bhanu Vaghashia is the current CEO of Globela Pharma.

Globela Pharma is a funded company, having raised a total of $11.37M across 3 funding rounds to date.

As of Mar 08, 2025, the latest employee count at Globela Pharma is 150.

Annual revenue of Globela Pharma is $30.53M as on Mar 31, 2024.

Globela Pharma was established in 1996 in Surat, India, within the pharmaceutical sector. Various finished formulations, including tablets, capsules, syrups, and injectables, are produced across therapeutic areas such as antibiotics, analgesics, cardiovascular drugs, anticancer treatments, gastrointestinal remedies, multivitamins, and additional categories. Manufacturing operations are supported by facilities certified under ISO 9001:2015 and WHO-GMP standards.

Globela Pharma's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.

Globela Pharma offers Finished Dosage Formulations, APIs, Intermediates, and DC Granules and Pellets.

Globela Pharma has 8 investors. Key investors include Somerset Indus Capital Partners, Karthic Jayaraman, Firoze Jehangir Irani, Rasik M Gondalia, and Biren V Gondaliya.

The valuation of Globela Pharma is $51.09M as of Jan 2022.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available